Pablo Demelo‐Rodríguez

Hospital General Universitario Gregorio Marañón

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Francisco Galeano‐Valle

Universidad Complutense de Madrid

Crhistian‐Mario Oblitas

Hospital General Universitario Gregorio Marañón

Lucía Ordieres‐Ortega

Hospital General Universitario Gregorio Marañón

Manuel Monréal

Universidad Católica San Antonio de Murcia

Jorge del Toro‐Cervera

Hospital General Universitario Gregorio Marañón

Jorge del-Toro-Cervera

Hospital General Universitario Gregorio Marañón

Carmine Siniscalchi

Ospedale di Parma

David Jiménez

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

Carmen Fernández‐Capitán

Hospital Universitario La Paz

A. Gil-Díaz

Hospital Universitario de Gran Canaria Doctor Negrín

Cooperative Institutions

Hospital General Universitario Gregorio Marañón

200

Universidad Católica San Antonio de Murcia

179

Hospital Universitari Germans Trias i Pujol

156

Universitat Autònoma de Barcelona

109

Universidad Complutense de Madrid

100

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

Instituto de Salud Carlos III

Bayer (United States)

Sanofi (Mexico)

Hospital Universitario La Paz

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

May-Thurner syndrome and deep vein thrombosis: A series of 8 patients

Medicina Clínica (English Edition) (2021)

Alejandra García-García Crhistian‐Mario Oblitas Francisco Galeano‐Valle Andrea Olmos-Nieto Ana Ortega-Soudant

May–Thurner syndrome

10.1016/j.medcle.2020.11.020

Cite

Citations (0)

Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels

Thrombosis Update (2020)

Ido Weinberg Carmen Fernández‐Capitán Manuel Quintana‐Díaz Pablo Demelo‐Rodríguez Gonzalo García de Casasola Sánchez

Hospitalized patients with COVID-19 and raised D-dimer levels have high rates of venous thromboembolism (VTE).

D-dimer

10.1016/j.tru.2020.100029

Cite

Citations (11)

Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism

Circulation Cardiovascular Imaging (2020)

Ghazaleh Mehdipoor David Jiménez Laurent Bertoletti Ángeles Fidalgo Juan Francisco Sánchez Muñoz-Torrero

Background: The choice of the imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider, patient or hospital characteristics, or over time. However, little is known about the choice of the diagnostic modalities in practice. The aim of this study was to evaluate the variations in the use of imaging modalities for patients with acute PE. Methods: Using the data from Registro Informatizado Enfermedad TromboEmbolica (RIETE), a prospective international registry of patients with venous thromboembolism (March 2001–January 2019), we explored the imaging modalities used in patients with acute PE. The imaging modalities included computed tomography pulmonary angiography, ventilation/perfusion scanning, pulmonary angiography, a combination of these tests, or PE signs and symptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging. Results: Among 38 025 patients with confirmed PE (53.1% female, age: 67.3±17 years), computed tomography pulmonary angiography was the dominant modality of diagnosis in all RIETE enrollees (78.2% [99% CI, 77.6–78.7]); including pregnant patients (58.9% [99% CI, 47.7%–69.4%]) and patients with severe renal insufficiency (62.5% [99% CI, 59.9–65.0]). A greater proportion of patients underwent ventilation/perfusion scanning in larger hospitals compared with smaller hospitals (13.1% versus 7.3%, P <0.001). The use of computed tomography pulmonary angiography varied between 13.3% and 98.3% across the countries, and its use increased over time (46.5% in 2002 to 91.7% in 2018, P <0.001). Conclusions: In a large multinational PE registry, variations were observed in the use of imaging modalities according to patient or institutional factors and over time. However, computed tomography pulmonary angiography was the dominant modality of diagnosis, even in pregnancy and severe renal insufficiency. The safety, costs, and downstream effects of these tests on PE-related and non-PE-related outcomes warrant further investigation.

Pulmonary angiography

Computed Tomography Angiography

Modalities

10.1161/circimaging.120.010651

Cite

Citations (12)

Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry

Journal of Thrombosis and Thrombolysis (2024)

Omri Cohen Gili Kenet Sarina Levy‐Mendelovich Inna Tzoran Benjamin Brenner

Protein C deficiency

Edoxaban

10.1007/s11239-024-02957-4

Cite

Citations (3)

Síndrome de las mejillas abofeteadas en el adulto

Medicina Clínica (2019)

Eva Cervilla‐Muñoz Francisco Galeano‐Valle Jorge del-Toro-Cervera Pablo Demelo‐Rodríguez

10.1016/j.medcli.2018.12.003

Cite

Citations (0)

Evaluation of simple laboratory parameters in SARS-CoV-2 infection: the role of ratios

Infectious Diseases (2022)

Crhistian‐Mario Oblitas Francisco Galeano‐Valle Carmen Cuenca-Carvajal Sandra Piqueras-Ruiz Rubén Alonso-Beato

Background The real predictive prognostic capacity of cellular indices (or ratios) is unclear in SARS-CoV-2 infection. This study aimed to assess the prognostic role of previously well-known laboratory indices and new ones in hospitalized COVID-19 patients.

Univariate analysis

10.1080/23744235.2022.2131902

Cite

Citations (2)

Role of Cytokines in Predicting Early Major Bleeding in Patients With Acute Pulmonary Embolism

European Journal Of Haematology (2025)

Crhistian‐Mario Oblitas Marta‐Olimpia Lago‐Rodríguez Marina López‐Rubio Mercedes García‐Gámiz Angielys Zamora‐Trillo

ABSTRACT Introduction Anticoagulant therapy is critical for venous thromboembolism (VTE) management, though bleeding remains a major concern, ranging from mild to fatal events. This study aimed to assess the predictive value of cytokines for major bleeding in patients with acute pulmonary embolism (PE). Methods In this prospective, observational study, patients aged ≥ 18 years with acute PE were enrolled from April 2021 to September 2022 and followed for 30 days. Exclusion criteria included asymptomatic PE, VTE without PE, and chronic anticoagulation. Major bleeding was defined as bleeding that required ≥ 2 transfused units of red blood cells, occurred in critical areas, or was fatal. Blood samples were collected at diagnosis to measure IL‐6, IL‐1beta, IL‐8, IL‐10, and TNF‐alpha. Statistical analyses used bivariate and multivariate logistic regression ( p < 0.05). Results Out of 191 patients (mean age 68.6 years, 52.9% male), 8.4% died, and 4.2% experienced major bleeding within 30 days. IL‐8 > 40 pg/mL and TNF‐alpha > 8.5 pg/mL were linked to major bleeding. IL‐8 > 40 pg/mL independently predicted early major bleeding (adjusted OR 9.40; 95% CI 1.38–63.69). Cox regression showed HRs of 12.60 for IL‐8 and 5.61 for TNF‐alpha. Conclusion High IL‐8 levels at diagnosis were predictive of major bleeding in acute PE patients. Further studies are required to confirm these findings.

Major bleeding

10.1111/ejh.14387

Cite

Citations (0)

Omalizumab as a Provoking Factor for Venous Thromboembolism

Drug Target Insights (2019)

Crhistian‐Mario Oblitas Francisco Galeano‐Valle Laura Vela-De La Cruz Jorge del Toro‐Cervera Pablo Demelo‐Rodríguez

A 43-year-old man with a history of severe extrinsic allergic asthma treated with once-monthly omalizumab (600 mg) for the last 15 months. He presented to the emergency room with a 2-week history of right lower limb pain and chest pleuritic pain. Computed tomography pulmonary angiography showed bilateral pulmonary embolism with right-sided pulmonary infarction and ultrasound of right lower limb confirmed distal deep vein thrombosis. No other known risk factors were identified. Treatment with omalizumab was stopped during hospitalization. The Naranjo Adverse Drug Reaction (ADR) Probability Scale classifies this as a probable ADR (score of 6). Omalizumab is a humanized monoclonal anti-IgE antibody indicated for the treatment of persistent moderate-to-severe asthma and certain chronic refractory urticaria. The EXCELS study (The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma), a postmarketing observational cohort study to assess clinical safety profile of omalizumab, showed a significant increase in venous thromboembolism. In conclusion, omalizumab has been associated with arterial and venous thromboembolic events, although the evidence is not definitive.

Omalizumab

Postmarketing surveillance

10.1177/1177392819861987

Cite

Citations (14)

Conociendo a los tutores de Medicina Interna: nuevas necesidades para la formación

Revista Clínica Española (2018)

Javier Moreno Díaz M. Aranda Sánchez A. González-Munera Pablo Demelo‐Rodríguez Daniel Martín‐Iglesias

10.1016/j.rce.2018.06.009

Cite

Citations (3)

1515 - INTEGRACIÓN DE MUTACIONES GENÉTICAS EMERGENTES Y EPIDEMIOLOGÍA EN PACIENTES CON ENFERMEDAD TROMBOEMBÓLICA VENOSA

Revista Clínica Española (2024)

Sergio Moragón Ledesma Francisco Galeano Valle Gustavo Duque Crhistian‐Mario Oblitas Lucía Ordieres Ortega

10.1016/s0014-2565(24)00407-7

Cite

Citations (0)